Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working against Charles River in the near term to make the stock ...

Charged with rape, Dr. Derrick Todd allegedly sexually assaulted patients under the guise of legitimate medical exams, ...

In Upslope’s view, CRL is a cyclical compounder going through a…cyclical downturn. Why are we bullish CRL stock? Click here ...

At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in ...

Mizuho Securities analyst Ann Hynes has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.Stay Ahead of the ...

Apollo for Biologics: Provides a centralized platform to submit sample submission forms, track samples, and exchange documents all in one place, ensuring accuracy and saving time.